Thromboangiitis obliterans(TAO)is a rare,chronic,progressive,and segmental inflammatory disease characterized by a high rate of amputation,significantly compromising the quality of life of patients.Si-Miao-Yong-An dec...Thromboangiitis obliterans(TAO)is a rare,chronic,progressive,and segmental inflammatory disease characterized by a high rate of amputation,significantly compromising the quality of life of patients.Si-Miao-Yong-An decoction(SMYA),a tradition-al prescription,exhibits anti-inflammatory,anti-thrombotic,and various other pharmacological properties.Clinically,it was fully proved to be effective for TAO therapy,but the specific therapeutic effect of SMYA on TAO has been unknown.Thus,deep unveiling the mechanism of SMYA in TAO for identifying clinical therapeutic targets is extremely important.In this study,we observed elev-ated levels of IL-17A in the peripheral blood mononuclear cells(PBMCs)of TAO patients,whereas the expression of miR-548j-5p was significantly decreased.A negative correlation between the levels of miR-548j-5p and IL-17A was also demonstrated.In vitro ex-periments showed that overexpression of miR-548j-5p led to a decrease in IL-17A levels,whereas downregulation of miR-548j-5p showed the opposite effect.Using a dual luciferase assay,we confirmed that miR-548j-5p directly targets IL-17A.Furthermore,serum containing SMYA effectively decreased IL-17A levels by increasing the expression of miR-548j-5p.More importantly,the results of in vivo tests indicated that SMYA mitigated the development of TAO by inhibiting IL-17A through the upregulation of miR-548j-5p in vascular tissues.In conclusion,SMYA significantly enhances the expression of miR-548j-5p,thereby reducing the levels of the target gene IL-17A and alleviating TAO.Our research not only identifies novel targets and pathways for the clinical diagnosis and treatment of TAO but also advances the innovation in traditional Chinese medicine through the elucidation of the SMYA/miR-548j-5p/IL-17A regulatory axis in the pathogenesis of TAO.展开更多
[目的]探讨宫颈癌紫杉醇抗性形成的潜在机制。[方法]紫杉醇浓度从0.001μmol/L逐渐递增至0.1μmol/L处理Hela细胞超过12个月进行Hela紫杉醇抗性细胞(Hela/TR)的筛选。检测Hela与Hela/TR细胞的细胞活力、凋亡水平、细胞周期和肿瘤干细胞...[目的]探讨宫颈癌紫杉醇抗性形成的潜在机制。[方法]紫杉醇浓度从0.001μmol/L逐渐递增至0.1μmol/L处理Hela细胞超过12个月进行Hela紫杉醇抗性细胞(Hela/TR)的筛选。检测Hela与Hela/TR细胞的细胞活力、凋亡水平、细胞周期和肿瘤干细胞水平。紫杉醇处理后,检测Hela与Hela/TR细胞内紫杉醇浓度。[结果]紫杉醇处理可以显著抑制Hela细胞的增殖并且诱导细胞凋亡。与Hela细胞相比,Hela/TR细胞中CD44^(+)细胞的比例显著增加,并且Hela/TR细胞中肿瘤干细胞标志物SOX2和ALDH1的表达水平高于Hela细胞。与Hela细胞相比,Hela/TR细胞的细胞内紫杉醇浓度明显降低(0.0759±0.0130 vs 0.0031±0.0004,t=12.52,P<0.05)。与Hela细胞相比,Hela/TR细胞中ABCC5的表达水平显著上升(0.15±0.04 vs 0.72±0.04,t=22.53,P<0.05)。敲低ABCC5后,Hela/TR细胞的细胞内紫杉醇浓度明显升高。与Hela细胞相比,Hela/TR细胞中FOXM1的表达水平上升。敲低FOXM1后,Hela/TR细胞中ABCC5的表达水平下降(0.13±0.07 vs 0.64±0.03,t=14.97,P<0.05),细胞内紫杉醇浓度明显上升。过表达miR-548o-3p后,Hela/TR细胞中FOXM1和ABCC5的水平表达下降,细胞内紫杉醇浓度明显上升(0.003±0.000 vs 0.072±0.010,t=15.43,P<0.05)。miR-548o-3p靶向FOXM1 mRNA的3′端非翻译区。过表达miR-548o-3p后,Hela/TR细胞对紫杉醇的抵抗显著下降(0.51±0.05 vs 0.10±0.01,t=17.98,P<0.05)。[结论]宫颈癌紫杉醇抗性细胞中miR-548o-3p负反馈失调导致FOXM1/ABCC5轴过度激活,提升了紫杉醇从宫颈癌细胞内的排除效率,增强了宫颈癌细胞的活力。展开更多
基金supported by the Natural Sci-ence Foundation of China(No.82274575)Co-construction Project of State Administration of TCM(Nos.GZY-KJS-SD-2023-034,GZY-KJS-SD-2023-046)+4 种基金Major Basic Research Project of Natural Science Foundation of Shandong Province(No.ZR2023ZD56)the Joint Fund of Natural Science Foundation of Shandong(No.ZR2022LZY011)the Central Government Guides Local Science and Technology Development Fund Projects of Shandong Province(No.YDZX20203700001407)Taishan Scholars(No.Tsqn201812125)National Youth Qihuang Scholar Training Program,Shandong Province Traditional Chinese Medicine High Level Talent Cultivation Project and Key research and development project of Shandong Province(No.2020CXGC010505).
文摘Thromboangiitis obliterans(TAO)is a rare,chronic,progressive,and segmental inflammatory disease characterized by a high rate of amputation,significantly compromising the quality of life of patients.Si-Miao-Yong-An decoction(SMYA),a tradition-al prescription,exhibits anti-inflammatory,anti-thrombotic,and various other pharmacological properties.Clinically,it was fully proved to be effective for TAO therapy,but the specific therapeutic effect of SMYA on TAO has been unknown.Thus,deep unveiling the mechanism of SMYA in TAO for identifying clinical therapeutic targets is extremely important.In this study,we observed elev-ated levels of IL-17A in the peripheral blood mononuclear cells(PBMCs)of TAO patients,whereas the expression of miR-548j-5p was significantly decreased.A negative correlation between the levels of miR-548j-5p and IL-17A was also demonstrated.In vitro ex-periments showed that overexpression of miR-548j-5p led to a decrease in IL-17A levels,whereas downregulation of miR-548j-5p showed the opposite effect.Using a dual luciferase assay,we confirmed that miR-548j-5p directly targets IL-17A.Furthermore,serum containing SMYA effectively decreased IL-17A levels by increasing the expression of miR-548j-5p.More importantly,the results of in vivo tests indicated that SMYA mitigated the development of TAO by inhibiting IL-17A through the upregulation of miR-548j-5p in vascular tissues.In conclusion,SMYA significantly enhances the expression of miR-548j-5p,thereby reducing the levels of the target gene IL-17A and alleviating TAO.Our research not only identifies novel targets and pathways for the clinical diagnosis and treatment of TAO but also advances the innovation in traditional Chinese medicine through the elucidation of the SMYA/miR-548j-5p/IL-17A regulatory axis in the pathogenesis of TAO.
文摘[目的]探讨宫颈癌紫杉醇抗性形成的潜在机制。[方法]紫杉醇浓度从0.001μmol/L逐渐递增至0.1μmol/L处理Hela细胞超过12个月进行Hela紫杉醇抗性细胞(Hela/TR)的筛选。检测Hela与Hela/TR细胞的细胞活力、凋亡水平、细胞周期和肿瘤干细胞水平。紫杉醇处理后,检测Hela与Hela/TR细胞内紫杉醇浓度。[结果]紫杉醇处理可以显著抑制Hela细胞的增殖并且诱导细胞凋亡。与Hela细胞相比,Hela/TR细胞中CD44^(+)细胞的比例显著增加,并且Hela/TR细胞中肿瘤干细胞标志物SOX2和ALDH1的表达水平高于Hela细胞。与Hela细胞相比,Hela/TR细胞的细胞内紫杉醇浓度明显降低(0.0759±0.0130 vs 0.0031±0.0004,t=12.52,P<0.05)。与Hela细胞相比,Hela/TR细胞中ABCC5的表达水平显著上升(0.15±0.04 vs 0.72±0.04,t=22.53,P<0.05)。敲低ABCC5后,Hela/TR细胞的细胞内紫杉醇浓度明显升高。与Hela细胞相比,Hela/TR细胞中FOXM1的表达水平上升。敲低FOXM1后,Hela/TR细胞中ABCC5的表达水平下降(0.13±0.07 vs 0.64±0.03,t=14.97,P<0.05),细胞内紫杉醇浓度明显上升。过表达miR-548o-3p后,Hela/TR细胞中FOXM1和ABCC5的水平表达下降,细胞内紫杉醇浓度明显上升(0.003±0.000 vs 0.072±0.010,t=15.43,P<0.05)。miR-548o-3p靶向FOXM1 mRNA的3′端非翻译区。过表达miR-548o-3p后,Hela/TR细胞对紫杉醇的抵抗显著下降(0.51±0.05 vs 0.10±0.01,t=17.98,P<0.05)。[结论]宫颈癌紫杉醇抗性细胞中miR-548o-3p负反馈失调导致FOXM1/ABCC5轴过度激活,提升了紫杉醇从宫颈癌细胞内的排除效率,增强了宫颈癌细胞的活力。
